None listed
Conditions
Interventions
Procedure/Surgery : 1. Pharmacopuncture therapy
This clinical trial is designed to compare the effectiveness of pharmacopunctrue as a combination therapy for chronic peripheral vertigo. The selection
Sponsors
Kyung Hee University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Male or female adults aged 19 to under 65 years 2) Patients diagnosed with peripheral vertigo (H81.0~H81.3) who have experienced persistent spinning dizziness for at least 4 weeks 3) Patients with a Dizziness Handicap Inventory (DHI) score of 16 of higher at screening 4) Patients who have signed the informed consent form provided in writing
Exclusion criteria
Exclusion criteria: 1) Individuals diagnosed with dizziness due to central nervous system disorders (e.g., cerebellar ataxia, cerebellar infarction/hemorrhage, demyelination, vertebrobasilar insufficiency, seizures, increased intracranial pressure, Parkinson’s disease, migraine) as confirmed by neurological examination and neuroimaging 2) Individuals diagnosed with cervicogenic dizziness 3) Individuals diagnosed with psychogenic dizziness 4) Individuals diagnosed with dizziness due to cardiovascular disorders (e.g., arrhythmia, valvular heart disease, anemia, orthostatic hypotension, coronary artery disease) 5) Individuals diagnosed with dizziness due to other active or uncontrolled conditions (e.g., uncontrolled diabetes, hypertension, other respiratory or endocrine disorders) 6) Individuals diagnosed with dizziness caused by current medications 7) Individuals diagnosed with severe chronic or terminal illnesses (e.g., malignant tumors, chronic renal failure, tuberculosis) 8) Individuals currently receiving treatment for chronic psychiatric disorders (e.g., epilepsy, depression, panic disorder) 9) Individuals with a severe allergy to bees or bee venom 10) Individuals who have received other treatments (e.g., nonsteroidal anti-inflammatory drugs, steroids) for vestibular dysfunction-related dizziness within the past week 11) Individuals who are pregnant, planning to become pregnant during the study period, or currently breastfeeding 12) Individuals suspected of alcohol or drug abuse 13) Individuals who participated in another clinical trial within one month prior to the intervention start date 14) Individuals with communication difficulties that would impede following the investigator’s instructions 15) Individuals deemed unsuitable for participation in the study by the principal investigator or study coordinator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in Dizziness Handicap Inventory (DHI) scores for diziness severity between baseline (V2) and the final assessment point (V9) | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in Vertigo Symptom Scale (VSS) scores for diziness severity between baseline (V2) and the final assessment point (V9);Difference in Vestibular Disorders Activities of Daily Living Scale (VADL) scores for diziness severity between baseline (V2) and the final assessment point (V9);Difference in Insomnia Severity Index (ISI) scores for insomnia symptoms between baseline (V2) and the final assessment point (V9);Difference in EQ-5D-5L and EQ-VAS scores for quality of life between baseline (V2) and the final assessment point (V9) using the EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L) | — |
Countries
Korea, Republic of
Contacts
Public ContactHyeri Lee
Kyung Hee University Oriental Medical Center
Outcome results
None listed